本文系基于公开资料撰写,仅作为信息交流之用,不构成任何投资建议。2025年,中国抗流感用药市场迎来“国产元年”。青峰医药的玛舒拉沙韦片、众生药业的昂拉地韦片、济川药业的玛硒洛沙韦片相继获批,成为首批上市的国产创新抗流感药。同时,健康元的玛帕西沙韦、先声药业的玛氘诺沙韦亦已提交新药上市申请,距离正式获批仅一步之遥。这些药品多为RNA聚合酶抑制剂,对标药物为罗氏旗下被称作“流感神药”的玛巴洛沙韦片(...
Source Link本文系基于公开资料撰写,仅作为信息交流之用,不构成任何投资建议。2025年,中国抗流感用药市场迎来“国产元年”。青峰医药的玛舒拉沙韦片、众生药业的昂拉地韦片、济川药业的玛硒洛沙韦片相继获批,成为首批上市的国产创新抗流感药。同时,健康元的玛帕西沙韦、先声药业的玛氘诺沙韦亦已提交新药上市申请,距离正式获批仅一步之遥。这些药品多为RNA聚合酶抑制剂,对标药物为罗氏旗下被称作“流感神药”的玛巴洛沙韦片(...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.